Zacks: Analysts Expect Juniper Pharmaceuticals, Inc. (JNP) Will Announce Earnings of -$0.11 Per Share
Wall Street analysts expect Juniper Pharmaceuticals, Inc. (NASDAQ:JNP) to report ($0.11) earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have issued estimates for Juniper Pharmaceuticals’ earnings. Juniper Pharmaceuticals reported earnings of $0.02 per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 650%. The business is expected to report its next quarterly earnings results on Tuesday, November 21st.
According to Zacks, analysts expect that Juniper Pharmaceuticals will report full-year earnings of ($0.39) per share for the current financial year. For the next fiscal year, analysts expect that the firm will report earnings of ($0.02) per share. Zacks’ earnings per share averages are a mean average based on a survey of analysts that follow Juniper Pharmaceuticals.
Juniper Pharmaceuticals (NASDAQ:JNP) last announced its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.13) by $0.10. Juniper Pharmaceuticals had a net margin of 13.94% and a return on equity of 21.49%. The company had revenue of $13.96 million during the quarter, compared to analyst estimates of $11.84 million.
A number of analysts have issued reports on JNP shares. ValuEngine downgraded shares of Juniper Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, June 2nd. BMO Capital Markets upgraded shares of Juniper Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price target for the company from $31.00 to $34.00 in a report on Friday, July 14th. Finally, HC Wainwright reiterated a “hold” rating on shares of Juniper Pharmaceuticals in a report on Monday, May 15th. Two analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and an average target price of $23.00.
Juniper Pharmaceuticals (NASDAQ JNP) opened at 4.40 on Friday. The company has a 50-day moving average of $4.66 and a 200 day moving average of $4.66. Juniper Pharmaceuticals has a 12 month low of $3.65 and a 12 month high of $6.40. The stock has a market capitalization of $47.71 million, a price-to-earnings ratio of 5.68 and a beta of 0.22.
COPYRIGHT VIOLATION WARNING: This piece was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.americanbankingnews.com/2017/09/09/zacks-analysts-expect-juniper-pharmaceuticals-inc-jnp-will-announce-earnings-of-0-11-per-share.html.
Several large investors have recently modified their holdings of the business. Goldman Sachs Group Inc. grew its stake in shares of Juniper Pharmaceuticals by 3.4% in the 2nd quarter. Goldman Sachs Group Inc. now owns 21,735 shares of the specialty pharmaceutical company’s stock worth $110,000 after buying an additional 715 shares in the last quarter. Acadian Asset Management LLC grew its stake in shares of Juniper Pharmaceuticals by 2.3% in the 2nd quarter. Acadian Asset Management LLC now owns 41,978 shares of the specialty pharmaceutical company’s stock worth $211,000 after buying an additional 941 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Juniper Pharmaceuticals by 1.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 72,875 shares of the specialty pharmaceutical company’s stock worth $368,000 after buying an additional 1,344 shares in the last quarter. Algert Global LLC grew its stake in shares of Juniper Pharmaceuticals by 10.8% in the 2nd quarter. Algert Global LLC now owns 120,035 shares of the specialty pharmaceutical company’s stock worth $606,000 after buying an additional 11,720 shares in the last quarter. Finally, TFS Capital LLC grew its stake in shares of Juniper Pharmaceuticals by 87.0% in the 1st quarter. TFS Capital LLC now owns 31,619 shares of the specialty pharmaceutical company’s stock worth $150,000 after buying an additional 14,707 shares in the last quarter. 36.20% of the stock is owned by institutional investors and hedge funds.
About Juniper Pharmaceuticals
Juniper Pharmaceuticals, Inc is a women’s health therapeutics company. The Company is focused on developing therapeutics that address unmet medical needs in women’s health. It operates in two segments: product and service. The product segment is engaged in manufacturing and supplying CRINONE, the Company’s commercialized product.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Juniper Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juniper Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.